Global The global contract research organization (CRO) market is estimated to be worth USD 76.6 billion in 2023 and is projected to reach USD 127.3 billion by 2028, growing at a CAGR of 10.7% from 2023 to 2028. Much of this growth is due to the need for novel clinical trial…
China A roundup of some of the biggest healthcare and pharma news from China, including the country’s struggle with a rampant COVID-19 outbreak and the external concern that surrounds it, China Meheco’s Paxlovid contract, Boston Scientific’s majority stake in Chinese medtech Acotec, Gracell Biotechnologies’ CAR-T therapy phase I trial 100 percent…
Global Driven by increased demand from Big Pharma, mid-caps, and biotechs for outsourcing services, the USD 70 billion global contract research organisation (CRO) market is predicted to grow at a CAGR of between 11 and 12 percent over the next five to seven years, with differing estimates placing its total size…
China The latest from Chinese pharma, including a drop in share prices for Chinese vaccine firms in the wake of successful COVID-19 trial results from western rivals, a new Pfizer-LianBio agreement, and Thermo Fisher’s new pharma services facility. China pharma shares fall as western rivals lead in vaccine trials https://www.ft.com/content/c4c8453e-39f6-4aac-83a3-7d16a3f4fa4b…
China Tony Acciarito, President of Thermo Fisher Scientific China, explains how he is delivering the company’s mission of ‘enabling our customers to make the world healthier, cleaner and safer’ in China, the importance of entrepreneurial thinking and agility to the China market, the significant investments they have made here, and his…
See our Cookie Privacy Policy Here